# Genmab A/S ADS (GMAB) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $33.60, market value $20.7 billion.

## Valuation
- **P/E (trailing): 26.7×** (5-yr avg 2.2×, 3-yr avg 2.2×). Genmab A/S ADS trades at 26.7× trailing earnings, well above its own five-year average of 2.2×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 21.1×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 5.0×**. Each dollar of revenue is priced at 5.0×.
- **Price / book: 3.4×**. The shares trade at 3.4× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 18.9×**. Enterprise value is 18.9× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 4.2%** (5-yr avg 61.9%). Free cash flow equals 4.2% of the market value, below its five-year average of 61.9%, so the shares are pricier on cash than usual.
- **Earnings yield: 3.8%**. The inverse of the P/E: 3.8% of the price is earned each year.

## Profitability
- **Gross margin: 93.0%**. Genmab A/S ADS keeps 93.0% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 32.3%**. 32.3% of revenue is left after running the business, an exceptional level.
- **Net margin: 25.9%**. 25.9% of each dollar of sales reaches the bottom line.
- **Return on equity: 16.5%**. 16.5% on shareholders' equity is solid.
- **Return on invested capital: 12.7%**. Return on all capital, debt included, is 12.7%.
- **Return on assets: 6.1%**. Each dollar of assets produces 6.1% of profit.

## Growth
- **Revenue growth (1 yr): 19.2%**. Revenue grew 19.2% over the last year.
- **EPS growth (1 yr): -12.3%**. Earnings per share fell 12.3%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.86**. Debt is 0.86 times equity, moderate leverage.
- **Net debt / EBITDA: 2.6×**. It would take 2.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 5.0×**. Operating profit covers interest 5.0× over, a safe margin.
- **Altman Z-score: 2.96**. A Z-score of 2.96 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Genmab A/S ADS does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 22.7%** (YTD 9.1%, 3-mo 33.6%). The shares are up 22.7% over twelve months including dividends.
- **From 52-week high: -5.2%** (42.3% above the low). Trading 5% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 60**. An RSI of 60 is neutral.
- **Beta (1 yr): 0.77** (volatility 33%). Beta of 0.77 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GMAB · Page: https://foliofundamentals.com/stocks/gmab

Not investment advice.